Humacyte, Inc.
HUMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Humacyte, Inc. (HUMA) is listed under Biotechnology. With a market capitalization of $308.6M, it sits in small-cap territory. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Market Cap
$308.6M
Beta
2.31
P/E (TTM)
—
P/E (Fwd)
-5.02
EPS (TTM)
$-0.63
EPS (Fwd)
$-0.28
ROE
-409.5%
ROA
-51.5%
Cash
$48.5M
Total Debt
$66.5M
Free CF
-$64.8M
52W Change
-47.1%
Annual Financials
Cash vs Debt
The company holds $48.5M in cash, though total debt stands at $66.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$64.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -409.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Humacyte, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Humacyte, Inc. and its sector.